Chronic proton pump inhibitor therapy and the risk of colorectal cancer
View abstract on PubMed
Summary
This summary is machine-generated.Long-term use of proton pump inhibitors (PPIs) for acid suppression does not significantly increase colorectal cancer risk. This study found no association between extended PPI therapy and developing colon cancer.
Area Of Science
- Gastroenterology
- Oncology
- Pharmacoepidemiology
Background
- Chronic acid suppression via proton pump inhibitor (PPI) therapy can elevate gastrin levels (hypergastrinemia).
- Previous research suggested a potential link between hypergastrinemia and colorectal cancer (CRC).
Purpose Of The Study
- To investigate whether long-term proton pump inhibitor use is associated with an increased risk of colorectal cancer.
- To examine duration-response and dose-response effects in a population-representative cohort.
Main Methods
- A nested case-control study was conducted using the UK General Practice Research Database (1987-2002).
- Included patients aged 50+ with at least 5 years of CRC-free follow-up.
- Matched 4432 CRC cases with 44,292 controls using incidence density sampling.
Main Results
- The adjusted odds ratio for CRC among patients with >= 5 years of PPI exposure was 1.1 (95% CI, 0.7-1.9).
- High-dose PPI users showed a non-significant trend towards increased risk with longer duration (P = .2).
- Patients with pernicious anemia did not exhibit an increased CRC risk (adjusted OR, 0.9; 95% CI, 0.6-1.3).
Conclusions
- Long-term proton pump inhibitor therapy at regular doses is not significantly associated with an increased risk of colorectal cancer.
- The findings suggest that PPIs do not elevate CRC risk in the general population.